Industries > Pharma > Plasma Protein Therapeutics Market Report 2021-2031
Plasma Protein Therapeutics Market Report 2021-2031
By Product (Immunoglobulin, Albumin, Coagulation Factor, C1-esterase inhibitors, and Others), By Application (Hemophilia, Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, and Other Indications), By Patient Demographics (Adults, Geriatric, Pediatric), By End User (Hospitals, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Leading Regional/ Country market analysis
Plasma Protein Therapeutics Market– our new study reveals trends, R&D progress, and predicted revenues
Where the Plasma Protein Therapeutics is market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
Our 260+ page report provides 360+ tables and 340+ charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Plasma Protein Therapeutics Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets
• Revenue and growth forecasts from 2021 to 2031 for the Global Plasma Protein Therapeutics Market By Product
• Immunoglobulin
• Albumin
• Coagulation Factor
• C1-esterase inhibitors
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Plasma Protein Therapeutics Market By Application
• Hemophilia
• Primary Immunodeficiency Disorder (PID)
• Idiopathic Thrombocytopenic Purpura
• Secondary Immunodeficiency
• Hereditary Angioedema
• Other Indications
• Revenue and growth forecasts from 2021 to 2031 for the Global Plasma Protein Therapeutics Market By Patient Demographics
• Adults
• Geriatric
• Pediatric
• Revenue and growth forecasts from 2021 to 2031 for the Global Plasma Protein Therapeutics Market By End User
• Hospitals
• Homecare
• Specialty Clinics
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Plasma Protein Therapeutics Market By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific
• Latin America
o Brazil
o Mexico
o Argentina
o Rest of Latin America
• Middle East and Africa
o Turkey
o Saudi Arabia
o South Africa
o UAE
o Egypt
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Plasma Protein Therapeutics Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Plasma Protein Therapeutics Market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Plasma Protein Therapeutics Market report helps you
In summary, our 260+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Plasma Protein Therapeutics Market, with forecasts for Get our report today Plasma Protein Therapeutics Market Forecast 2021-2031: By Product, By Application, Patient Demographics, End User, Distribution Channel and Leading Regional/ Country market analysis each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Plasma Protein Therapeutics market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Plasma Protein Therapeutics Market. Some of the company’s profiled in this report include
• Baxter International
• Biotests
• CSL Behring
• GRIFOLS, S.A
• Kedrion
• Octapharma USA, Inc.
• Shire Plc.
• China Biologics.
• Emergent BioSolutions
• Takeda Pharmaceutical Company Ltd
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Plasma Protein Therapeutics Market and leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Plasma Protein Therapeutics Market Report 2021-2031: By Product (Immunoglobulin, Albumin, Coagulation Factor, C1-esterase inhibitors, and Others), By Application (Hemophilia, Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, and Other Indications), By Patient Demographics (Adults, Geriatric, Pediatric), By End User (Hospitals, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Leading Regional/ Country market analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered By This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Plasma Protein Therapeutics Market
2.1. Plasma Protein Therapeutics Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Condition Submarkets Definitions
3. Plasma Protein Therapeutics Market Overview
3.1. Global Plasma Protein Therapeutics Market Size and Forecast By Region
3.2. Global Plasma Protein Therapeutics Market Share By Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Availability of Reimbursement in Developing Nations
3.3.1.2. Rapid Surge in the plasma protein therapeutics demand
3.3.1.3. Increasing geriatric population around the world
3.3.1.4. Increasing disposable income
3.3.1.5. Growing regulatory approvals for plasma protein therapeutics
3.3.2. Market Restraints
3.3.2.1. High cost of development
3.3.2.2. Unmet medical needs
3.3.3. Opportunities
3.3.3.1. Increasing therapeutic Advancements in plasma protein therapeutics
3.3.3.2. Growing awareness regarding consumption of Plasma Protein Therapeutics
3.3.4. Challenges
3.3.4.1. Availability of the alternatives
3.3.4.2. Side effects associated with the plasma protein therapeutics
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Plasma Protein Therapeutics Market Analysis and Forecast 2021-2031, By Product (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Immunoglobulin
4.1.1.1. Immunoglobulin market size and forecast, 2021-2031 (USD Million)
4.1.2. Albumin
4.1.2.1. Albumin market size and forecast, 2021-2031 (USD Million)
4.1.3. Coagulation Factor
4.1.3.1. Coagulation Factor market size and forecast, 2021-2031 (USD Million)
4.1.4. C1-esterase Inhibitors
4.1.4.1. C1-esterase Inhibitors market size and forecast, 2021-2031 (USD Million)
4.1.5. Others
4.1.5.1. Others market size and forecast, 2021-2031 (USD Million)
5. Global Plasma Protein Therapeutics Market Analysis and Forecast, 2021-2031 By Application (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Hemophilia
5.1.1.1. Hemophilia market size and forecast, 2021-2031 (USD Million)
5.1.2. Primary Immunodeficiency Disorder (PID)
5.1.2.1. Primary immunodeficiency disorder (PID) market size and forecast, 2021-2031 (USD Million)
5.1.3. Idiopathic Thrombocytopenic Purpura
5.1.3.1. Idiopathic Thrombocytopenic Purpura market size and forecast, 2021-2031 (USD Million)
5.1.4. Secondary Immunodeficiency
5.1.4.1. Secondary Immunodeficiency market size and forecast, 2021-2031 (USD Million)
5.1.5. Hereditary Angioedema
5.1.5.1. Hereditary Angioedema market size and forecast, 2021-2031 (USD Million)
5.1.6. Other Indications
5.1.6.1. Other Indications market size and forecast, 2021-2031 (USD Million)
6. Global Plasma Protein Therapeutics Market Analysis and Forecast, 2021-2031 By Patient Demographics (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Geriatric
6.1.1.1. Geriatric market size and forecast, 2021-2031 (USD Million)
6.1.2. Adult
6.1.2.1. Adult market size and forecast, 2021-2031 (USD Million)
6.1.3. Pediatric
6.1.3.1. Pediatric market size and forecast, 2021-2031 (USD Million)
7. Global Plasma Protein Therapeutics Market Analysis and Forecast, 2021-2031 By End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Hospitals
7.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
7.1.2. Homecare
7.1.2.1. Homecare market size and forecast, 2021-2031 (USD Million)
7.1.3. Specialty Clinics
7.1.3.1. Specialty Clinics market size and forecast, 2021-2031 (USD Million)
7.1.4. Others
7.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
8. Global Plasma Protein Therapeutics Market Analysis and Forecast, 2021-2031 By Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. Hospitals Pharmacy
8.1.1.1. Hospitals Pharmacy market size and forecast, 2021-2031 (USD Million)
8.1.2. Retail Pharmacy
8.1.2.1. Retail Pharmacy market size and forecast, 2021-2031 (USD Million)
8.1.3. Online Pharmacies
8.1.3.1. Online Pharmacies market size and forecast, 2021-2031 (USD Million)
9. North America Plasma Protein Therapeutics Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. North America Plasma Protein Therapeutics Market Size and Forecast By Product
9.2.1.1. XX Driving/Opportunity Factor
9.2.1.2. XX Driving/Opportunity Factor
9.3. North America Plasma Protein Therapeutics Market Size and Forecast By Application
9.3.1.1. XX Driving/Opportunity Factor
9.3.1.2. XX Driving/Opportunity Factor
9.4. North America Plasma Protein Therapeutics Market Size and Forecast By Patient Demographics
9.4.1.1. XX Driving/Opportunity Factor
9.4.1.2. XX Driving/Opportunity Factor
9.5. North America Plasma Protein Therapeutics Market Size and Forecast By End-User
9.5.1.1. XX Driving/Opportunity Factor
9.5.1.2. XX Driving/Opportunity Factor
9.6. North America Plasma Protein Therapeutics Market Size and Forecast By Distribution Channel
9.6.1.1. XX Driving/Opportunity Factor
9.6.1.2. XX Driving/Opportunity Factor
9.7. U.S. Plasma Protein Therapeutics Market
9.7.1.1. XX Driving/Opportunity Factor
9.7.1.2. XX Driving/Opportunity Factor
9.8. Canada Plasma Protein Therapeutics Market
9.8.1.1. XX Driving/Opportunity Factor
9.8.1.2. XX Driving/Opportunity Factor
10. Europe Plasma Protein Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Europe Plasma Protein Therapeutics Market Size and Forecast By Product
10.2.1.1. XX Driving/Opportunity Factor
10.2.1.2. XX Driving/Opportunity Factor
10.3. Europe Plasma Protein Therapeutics Market Size and Forecast By Application
10.3.1.1. XX Driving/Opportunity Factor
10.3.1.2. XX Driving/Opportunity Factor
10.4. Europe Plasma Protein Therapeutics Market Size and Forecast By Patient Demographics
10.4.1.1. XX Driving/Opportunity Factor
10.4.1.2. XX Driving/Opportunity Factor
10.5. Europe Plasma Protein Therapeutics Market Size and Forecast By End-User
10.5.1.1. XX Driving/Opportunity Factor
10.5.1.2. XX Driving/Opportunity Factor
10.6. Europe Plasma Protein Therapeutics Market Size and Forecast By Distribution Channel
10.6.1.1. XX Driving/Opportunity Factor
10.6.1.2. XX Driving/Opportunity Factor
10.7. UK Plasma Protein Therapeutics Market
10.7.1.1. XX Driving/Opportunity Factor
10.7.1.2. XX Driving/Opportunity Factor
10.8. Germany Plasma Protein Therapeutics Market
10.8.1.1. XX Driving/Opportunity Factor
10.8.1.2. XX Driving/Opportunity Factor
10.9. France Plasma Protein Therapeutics Market
10.9.1.1. XX Driving/Opportunity Factor
10.9.1.2. XX Driving/Opportunity Factor
10.10. Rest of Europe Plasma Protein Therapeutics Market
10.10.1.1. XX Driving/Opportunity Factor
10.10.1.2. XX Driving/Opportunity Factor
11. Asia Pacific Plasma Protein Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. Asia-Pacific Plasma Protein Therapeutics Market Size and Forecast By Product
11.2.1.1. XX Driving/Opportunity Factor
11.2.1.2. XX Driving/Opportunity Factor
11.3. Asia-Pacific Plasma Protein Therapeutics Market Size and Forecast By Application
11.3.1.1. XX Driving/Opportunity Factor
11.3.1.2. XX Driving/Opportunity Factor
11.4. Asia-Pacific Plasma Protein Therapeutics Market Size and Forecast By Patient Demographics
11.4.1.1. XX Driving/Opportunity Factor
11.4.1.2. XX Driving/Opportunity Factor
11.5. Asia-Pacific Plasma Protein Therapeutics Market Size and Forecast By End-User
11.5.1.1. XX Driving/Opportunity Factor
11.5.1.2. XX Driving/Opportunity Factor
11.6. Asia-Pacific Plasma Protein Therapeutics Market Size and Forecast By Distribution Channel
11.6.1.1. XX Driving/Opportunity Factor
11.6.1.2. XX Driving/Opportunity Factor
11.7. China Plasma Protein Therapeutics Market
11.7.1.1. XX Driving/Opportunity Factor
11.7.1.2. XX Driving/Opportunity Factor
11.8. India Plasma Protein Therapeutics Market
11.8.1.1. XX Driving/Opportunity Factor
11.8.1.2. XX Driving/Opportunity Factor
11.9. Japan Plasma Protein Therapeutics Market
11.9.1.1. XX Driving/Opportunity Factor
11.9.1.2. XX Driving/Opportunity Factor
11.10. Rest of Asia Pacific Plasma Protein Therapeutics Market
11.10.1.1. XX Driving/Opportunity Factor
11.10.1.2. XX Driving/Opportunity Factor
12. Latin America Plasma Protein Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. Latin America Plasma Protein Therapeutics Market Size and Forecast By Product
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. Latin America Plasma Protein Therapeutics Market Size and Forecast By Application
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. Latin America Plasma Protein Therapeutics Market Size and Forecast By Patient Demographics
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. Latin America Plasma Protein Therapeutics Market Size and Forecast By End-User
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. Latin America Plasma Protein Therapeutics Market Size and Forecast By Distribution Channel
12.7. Brazil Plasma Protein Therapeutics Market
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. Mexico Plasma Protein Therapeutics Market
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. Rest of Latin America Plasma Protein Therapeutics Market
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
13. MEA Plasma Protein Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. MEA Plasma Protein Therapeutics Market Size and Forecast By Product
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. MEA Plasma Protein Therapeutics Market Size and Forecast By Application
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. MEA Plasma Protein Therapeutics Market Size and Forecast By Patient Demographics
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. MEA Plasma Protein Therapeutics Market Size and Forecast By End-User
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. MEA Plasma Protein Therapeutics Market Size and Forecast By Distribution Channel
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. GCC Plasma Protein Therapeutics Market
13.7.1.1. XX Driving/Opportunity Factor
13.7.1.2. XX Driving/Opportunity Factor
13.8. South Africa Plasma Protein Therapeutics Market
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. Rest of MEA Plasma Protein Therapeutics Market
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
14. Companies in the Plasma Protein Therapeutics Market
14.1. Baxter International
14.1.1. Company Snapshot
14.1.2. Company Overview
14.1.3. Financial Performance (2015-2019)
14.1.3.1. Net Revenue
14.1.3.2. Gross Profit
14.1.3.3. Geographical Revenue, 2019
14.1.4. Product Offerings
14.1.5. Recent Initiatives (2017-2019)
14.2. Biotests
14.2.1. Company Snapshot
14.2.2. Company Overview
14.2.3. Financial Performance (2015-2019)
14.2.3.1. Net Revenue
14.2.3.2. Gross Profit
14.2.3.3. Geographical Revenue, 2019
14.2.4. Product Offerings
14.2.5. Recent Initiatives (2017-2019)
14.3. CSL Behring
14.3.1. Company Snapshot
14.3.2. Company Overview
14.3.3. Financial Performance (2015-2019)
14.3.3.1. Net Revenue
14.3.3.2. Gross Profit
14.3.3.3. Geographical Revenue, 2019
14.3.4. Product Offerings
14.3.5. Recent Initiatives (2017-2019)
14.4. GRIFOLS, S.A
14.4.1. Company Snapshot
14.4.2. Company Overview
14.4.3. Financial Performance (2015-2019)
14.4.3.1. Net Revenue
14.4.3.2. Gross Profit
14.4.3.3. Geographical Revenue, 2019
14.4.4. Product Offerings
14.4.5. Recent Initiatives (2017-2019)
14.5. KEDRION
14.5.1. Company Snapshot
14.5.2. Company Overview
14.5.3. Financial Performance (2015-2019)
14.5.3.1. Net Revenue
14.5.3.2. Gross Profit
14.5.3.3. Geographical Revenue, 2019
14.5.4. Product Offerings
14.5.5. Recent Initiatives (2017-2019)
14.6. Octapharma USA, Inc.
14.6.1. Company Snapshot
14.6.2. Company Overview
14.6.3. Financial Performance (2015-2019)
14.6.3.1. Net Revenue
14.6.3.2. Gross Profit
14.6.3.3. Geographical Revenue, 2019
14.6.4. Product Offerings
14.6.5. Recent Initiatives (2017-2019)
14.7. Shire Plc.
14.7.1. Company Snapshot
14.7.2. Company Overview
14.7.3. Financial Performance (2015-2019)
14.7.3.1. Net Revenue
14.7.3.2. Gross Profit
14.7.3.3. Geographical Revenue, 2019
14.7.4. Product Offerings
14.7.5. Recent Initiatives (2017-2019)
14.8. China Biologics.
14.8.1. Company Snapshot
14.8.2. Company Overview
14.8.3. Financial Performance (2015-2019)
14.8.3.1. Net Revenue
14.8.3.2. Gross Profit
14.8.3.3. Geographical Revenue, 2019
14.8.4. Product Offerings
14.8.5. Recent Initiatives (2017-2019)
14.9. Emergent BioSolutions
14.9.1. Company Snapshot
14.9.2. Company Overview
14.9.3. Financial Performance (2015-2019)
14.9.3.1. Net Revenue
14.9.3.2. Gross Profit
14.9.3.3. Geographical Revenue, 2019
14.9.4. Product Offerings
14.9.5. Recent Initiatives (2017-2019)
14.10. Takeda Pharmaceutical Company Ltd
14.10.1. Company Snapshot
14.10.2. Company Overview
14.10.3. Financial Performance (2015-2019)
14.10.3.1. Net Revenue
14.10.3.2. Gross Profit
14.10.3.3. Geographical Revenue, 2019
14.10.4. Product Offerings
14.10.5. Recent Initiatives (2017-2019)
14.11. Other Notable Players
15. Conclusion
16. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Plasma Protein Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Plasma Protein Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Plasma Protein Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Plasma Protein Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Plasma Protein Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Plasma Protein Therapeutics Market Drivers & Restraints 2021
Table 7. Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Immunoglobulin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Immunoglobulin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Immunoglobulin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Immunoglobulin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Immunoglobulin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Albumin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Albumin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Albumin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Albumin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Albumin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Coagulation Factor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Coagulation Factor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Coagulation Factor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Coagulation Factor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Coagulation Factor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. C1-esterase Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. C1-esterase Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. C1-esterase Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. C1-esterase Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. C1-esterase Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Hemophilia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Hemophilia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Hemophilia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Hemophilia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Hemophilia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Primary Immunodeficiency Disorder (PID) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Primary Immunodeficiency Disorder (PID) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Primary Immunodeficiency Disorder (PID) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Primary Immunodeficiency Disorder (PID) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Primary Immunodeficiency Disorder (PID) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Secondary Immunodeficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Secondary Immunodeficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Secondary Immunodeficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Secondary Immunodeficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Secondary Immunodeficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Hereditary Angioedema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Hereditary Angioedema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Hereditary Angioedema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Hereditary Angioedema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Hereditary Angioedema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Other Indications Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Other Indications Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Other Indications Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Other Indications Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Other Indications Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 118. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 123. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 128. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 132. North America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 133. North America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 134. North America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 135. North America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 136. North America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 137. North America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 138. North America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 139. North America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 140. North America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 141. North America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 142. North America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 143. North America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 144. North America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 145. North America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 146. North America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 147. North America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 148. North America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 149. North America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150. North America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 151. North America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 152. North America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153. North America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. North America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 155. North America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 156. North America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157. North America Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. North America Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. North America Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. North America Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161. North America Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. US Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. US Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. US Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. US Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. US Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167. Canada Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168. Canada Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Canada Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Canada Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Canada Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Europe Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 173. Europe Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. Europe Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. Europe Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. Europe Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177. Europe Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. Europe Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. Europe Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. Europe Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. Europe Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. Europe Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183. Europe Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. Europe Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185. Europe Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. Europe Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. Europe Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. Europe Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. Europe Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. Europe Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191. Europe Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. Europe Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. Europe Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. Europe Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. Europe Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. Europe Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. Europe Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 198. Europe Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 199. Europe Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 200. Europe Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 201. UK Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 202. UK Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 203. UK Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 204. UK Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 205. UK Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 206. Germany Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 207. Germany Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 208. Germany Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 209. Germany Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 210. Germany Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 211. France Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 212. France Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 213. France Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 214. France Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 215. France Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 216. Rest of Europe Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 217. Rest of Europe Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 218. Rest of Europe Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 219. Rest of Europe Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 220. Rest of Europe Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 221. Asia Pacific Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 222. Asia Pacific Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 223. Asia Pacific Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 224. Asia Pacific Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 225. Asia Pacific Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 226. Asia Pacific Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 227. Asia Pacific Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 228. Asia Pacific Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 229. Asia Pacific Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 230. Asia Pacific Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 231. Asia Pacific Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 232. Asia Pacific Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 233. Asia Pacific Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 234. Asia Pacific Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 235. Asia Pacific Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 236. Asia Pacific Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 237. Asia Pacific Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 238. Asia Pacific Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 239. Asia Pacific Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 240. Asia Pacific Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 241. Asia Pacific Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 242. Asia Pacific Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 243. Asia Pacific Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 244. Asia Pacific Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 245. Asia Pacific Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 246. Asia Pacific Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 247. Asia Pacific Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 248. Asia Pacific Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 249. Asia Pacific Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 250. Asia Pacific Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 251. China Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 252. China Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 253. China Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 254. China Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 255. China Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 256. India Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 257. India Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 258. India Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 259. India Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 260. India Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 261. Japan Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 262. Japan Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 263. Japan Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 264. Japan Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 265. Japan Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 266. RoAPAC Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 267. RoAPAC Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 268. RoAPAC Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 269. RoAPAC Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 270. RoAPAC Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 271. Middle East Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 272. Middle East Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 273. Middle East Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 274. Middle East Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 275. Middle East Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 276. Middle East Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 277. Middle East Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 278. Middle East Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 279. Middle East Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 280. Middle East Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 281. Middle East Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 282. Middle East Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 283. Middle East Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 284. Middle East Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 285. Middle East Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 286. Middle East Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 287. Middle East Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 288. Middle East Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 289. Middle East Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 290. Middle East Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 291. Middle East Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 292. Middle East Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 293. Middle East Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 294. Middle East Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 295. Middle East Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 296. Latin America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 297. Latin America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 298. Latin America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 299. Latin America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 300. Latin America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 301. Latin America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 302. Latin America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 303. Latin America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 304. Latin America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 305. Latin America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 306. Latin America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 307. Latin America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 308. Latin America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 309. Latin America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 310. Latin America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 311. Latin America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 312. Latin America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 313. Latin America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 314. Latin America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 315. Latin America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 316. Latin America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 317. Latin America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 318. Latin America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 319. Latin America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 320. Latin America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 321. Africa Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 322. Africa Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 323. Africa Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 324. Africa Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 325. Africa Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 326. Africa Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 327. Africa Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 328. Africa Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 329. Africa Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 330. Africa Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 331. Africa Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 332. Africa Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 333. Africa Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 334. Africa Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 335. Africa Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 336. Africa Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 337. Africa Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 338. Africa Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 339. Africa Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 340. Africa Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 341. Africa Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 342. Africa Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 343. Africa Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 344. Africa Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 345. Africa Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 346. Leading 10 Plasma Protein Therapeutics Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 347. Baxter InternationalProfile 2019 (CEO, HQ, Founded, Website)
Table 348. Baxter International Plasma Protein Therapeutics Product Offering (Segment, Product Offerings)
Table 349. Biotests Profile 2019 (CEO, HQ, Founded, Website)
Table 350. Biotests Plasma Protein Therapeutics Product Offering (Segment, Product Offerings)
Table 351. CSL Behring Profile 2019 (CEO, HQ, Founded, Website)
Table 352. CSL Behring.Plasma Protein Therapeutics Product Offering (Segment, Product Offerings)
Table 353. GRIFOLS, S.A Profile 2019 (CEO, HQ, Founded, Website)
Table 354. GRIFOLS, S.A Plasma Protein Therapeutics Product Offering (Segment, Product Offerings)
Table 355. KEDRION Profile 2019 (CEO, HQ, Founded, Website)
Table 356. KEDRION Plasma Protein Therapeutics Product Offering (Segment, Product Offerings)
Table 357. Octapharma USA, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 358. Octapharma USA, Inc. Plasma Protein Therapeutics Product Offering (Segment, Product Offerings)
Table 359. Shire Plc. Profile 2019 (CEO, HQ, Founded, Website)
Table 360. Shire Plc. Plasma Protein Therapeutics Product Offering (Segment, Product Offerings)
Table 361. China Biologics. Profile 2019 (CEO, HQ, Founded, Website)
Table 362. China Biologics. Plasma Protein Therapeutics Product Offering (Segment, Product Offerings)
Table 363. Emergent BioSolutions Profile 2019 (CEO, HQ, Founded, Website)
Table 364. Emergent BioSolutions Plasma Protein Therapeutics Product Offering (Segment, Product Offerings)
Table 365. Takeda Pharmaceutical Company Ltd Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 366. Takeda Pharmaceutical Company Ltd Plasma Protein Therapeutics Product Offering (Segment, Product Offerings)
Table 367. Other Companies Involved in the Plasma Protein Therapeutics Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Plasma Protein Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Plasma Protein Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Plasma Protein Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Plasma Protein Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Plasma Protein Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Plasma Protein Therapeutics Market Drivers & Restraints 2021
Figure 7. Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. Immunoglobulin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. Immunoglobulin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. Immunoglobulin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. Immunoglobulin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. Immunoglobulin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Albumin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Albumin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Albumin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Albumin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Albumin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Coagulation Factor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Coagulation Factor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Coagulation Factor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Coagulation Factor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Coagulation Factor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. C1-esterase Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. C1-esterase Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. C1-esterase Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. C1-esterase Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. C1-esterase Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 33. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Hemophilia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Hemophilia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Hemophilia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Hemophilia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Hemophilia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Primary Immunodeficiency Disorder (PID) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Primary Immunodeficiency Disorder (PID) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Primary Immunodeficiency Disorder (PID) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Primary Immunodeficiency Disorder (PID) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Primary Immunodeficiency Disorder (PID) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Secondary Immunodeficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Secondary Immunodeficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Secondary Immunodeficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Secondary Immunodeficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Secondary Immunodeficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Hereditary Angioedema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Hereditary Angioedema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Hereditary Angioedema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Hereditary Angioedema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Hereditary Angioedema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Other Indications Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Other Indications Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Other Indications Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Other Indications Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Other Indications Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 118. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 123. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 128. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. North America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 133. North America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. North America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. North America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. North America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. North America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 138. North America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. North America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. North America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. North America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. North America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 143. North America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 144. North America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 145. North America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 146. North America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 147. North America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 148. North America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 149. North America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 150. North America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 151. North America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 152. North America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 153. North America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 154. North America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 155. North America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 156. North America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 157. North America Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 158. North America Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 159. North America Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 160. North America Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 161. North America Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 162. US Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 163. US Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 164. US Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 165. US Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 166. US Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 167. Canada Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 168. Canada Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 169. Canada Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 170. Canada Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 171. Canada Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 172. Europe Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 173. Europe Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 174. Europe Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 175. Europe Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 176. Europe Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 177. Europe Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 178. Europe Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 179. Europe Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 180. Europe Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 181. Europe Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 182. Europe Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 183. Europe Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 184. Europe Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 185. Europe Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 186. Europe Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 187. Europe Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 188. Europe Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 189. Europe Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 190. Europe Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 191. Europe Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 192. Europe Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 193. Europe Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 194. Europe Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 195. Europe Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 196. Europe Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 197. Europe Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 198. Europe Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 199. Europe Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 200. Europe Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 201. UK Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 202. UK Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 203. UK Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 204. UK Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 205. UK Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 206. Germany Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 207. Germany Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 208. Germany Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 209. Germany Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 210. Germany Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 211. France Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 212. France Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 213. France Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 214. France Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 215. France Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 216. Rest of Europe Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 217. Rest of Europe Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 218. Rest of Europe Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 219. Rest of Europe Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 220. Rest of Europe Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 221. Asia Pacific Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 222. Asia Pacific Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 223. Asia Pacific Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 224. Asia Pacific Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 225. Asia Pacific Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 226. Asia Pacific Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 227. Asia Pacific Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 228. Asia Pacific Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 229. Asia Pacific Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 230. Asia Pacific Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 231. Asia Pacific Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 232. Asia Pacific Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 233. Asia Pacific Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 234. Asia Pacific Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 235. Asia Pacific Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 236. Asia Pacific Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 237. Asia Pacific Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 238. Asia Pacific Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 239. Asia Pacific Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 240. Asia Pacific Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 241. Asia Pacific Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 242. Asia Pacific Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 243. Asia Pacific Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 244. Asia Pacific Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 245. Asia Pacific Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 246. Asia Pacific Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 247. Asia Pacific Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 248. Asia Pacific Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 249. Asia Pacific Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 250. Asia Pacific Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 251. China Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 252. China Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 253. China Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 254. China Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 255. China Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 256. India Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 257. India Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 258. India Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 259. India Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 260. India Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 261. Japan Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 262. Japan Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 263. Japan Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 264. Japan Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 265. Japan Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 266. RoAPAC Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 267. RoAPAC Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 268. RoAPAC Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 269. RoAPAC Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 270. RoAPAC Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 271. Middle East Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 272. Middle East Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 273. Middle East Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 274. Middle East Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 275. Middle East Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 276. Middle East Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 277. Middle East Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 278. Middle East Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 279. Middle East Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 280. Middle East Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 281. Middle East Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 282. Middle East Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 283. Middle East Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 284. Middle East Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 285. Middle East Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 286. Middle East Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 287. Middle East Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 288. Middle East Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 289. Middle East Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 290. Middle East Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 291. Middle East Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 292. Middle East Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 293. Middle East Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 294. Middle East Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 295. Middle East Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 296. Latin America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 297. Latin America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 298. Latin America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 299. Latin America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 300. Latin America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 301. Latin America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 302. Latin America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 303. Latin America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 304. Latin America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 305. Latin America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 306. Latin America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 307. Latin America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 308. Latin America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 309. Latin America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 310. Latin America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 311. Latin America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 312. Latin America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 313. Latin America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 314. Latin America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 315. Latin America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 316. Latin America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 317. Latin America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 318. Latin America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 319. Latin America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 320. Latin America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 321. Africa Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 322. Africa Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 323. Africa Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 324. Africa Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 325. Africa Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 326. Africa Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 327. Africa Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 328. Africa Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 329. Africa Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 330. Africa Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 331. Africa Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 332. Africa Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 333. Africa Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 334. Africa Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 335. Africa Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 336. Africa Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 337. Africa Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 338. Africa Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 339. Africa Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 340. Africa Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 341. Africa Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 342. Africa Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 343. Africa Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 344. Africa Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 345. Africa Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 346. Porter’s Five Force Analysis
Companies Mentioned
1. AbbVie
2. Achaogen
3. Actavis
4. Actelion
5. Affinium Pharmaceutical
6. AiCuris GmbH & Co. KG
7. Alcon
8. Alkem Laboratories
9. Allergan
10. Allied Pharma
11. Apotex
12. APP Pharmaceuticals
13. Aptalis Pharma
14. Aquapharm Biodiscovery
15. Cempra Pharmaceuticals
16. Cipla
17. Claris Lifesciences
18. Cornerstone Biopharma
19. Cornerstone Therapeutics
20. Corona Remedies
21. Eli Lilly
22. Gate Pharma
23. Gilead Sciences
24. GlaxoSmithKline (GSK)
25. Glenmark
26. GlycoVaxyn
27. Hetero
28. Hikma Farmaceutica
29. Hi-Tech Pharma
30. Hospira
31. Macleod Pharmaceuticals
32. Microlabs
33. Nalneva
34. Novartis
35. Novexel
36. Paratek Pharmaceuticals
37. Pfizer
38. Ranbaxy
39. Roche
40. Sagent Pharmaceuticals
41. Sandoz
42. Sanofi
43. Sequella
44. Shanghai MengKe Pharmaceuticals
45. Shionogi
46. SHIONOGI Co., Ltd.
47. Shire
48. Sidmak Labs
49. Solitaire Pharmacia
50. Specialised Therapeutics Australia
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered By This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Plasma Protein Therapeutics Market
2.1. Plasma Protein Therapeutics Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Condition Submarkets Definitions
3. Plasma Protein Therapeutics Market Overview
3.1. Global Plasma Protein Therapeutics Market Size and Forecast By Region
3.2. Global Plasma Protein Therapeutics Market Share By Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Availability of Reimbursement in Developing Nations
3.3.1.2. Rapid Surge in the plasma protein therapeutics demand
3.3.1.3. Increasing geriatric population around the world
3.3.1.4. Increasing disposable income
3.3.1.5. Growing regulatory approvals for plasma protein therapeutics
3.3.2. Market Restraints
3.3.2.1. High cost of development
3.3.2.2. Unmet medical needs
3.3.3. Opportunities
3.3.3.1. Increasing therapeutic Advancements in plasma protein therapeutics
3.3.3.2. Growing awareness regarding consumption of Plasma Protein Therapeutics
3.3.4. Challenges
3.3.4.1. Availability of the alternatives
3.3.4.2. Side effects associated with the plasma protein therapeutics
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Plasma Protein Therapeutics Market Analysis and Forecast 2021-2031, By Product (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Immunoglobulin
4.1.1.1. Immunoglobulin market size and forecast, 2021-2031 (USD Million)
4.1.2. Albumin
4.1.2.1. Albumin market size and forecast, 2021-2031 (USD Million)
4.1.3. Coagulation Factor
4.1.3.1. Coagulation Factor market size and forecast, 2021-2031 (USD Million)
4.1.4. C1-esterase Inhibitors
4.1.4.1. C1-esterase Inhibitors market size and forecast, 2021-2031 (USD Million)
4.1.5. Others
4.1.5.1. Others market size and forecast, 2021-2031 (USD Million)
5. Global Plasma Protein Therapeutics Market Analysis and Forecast, 2021-2031 By Application (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Hemophilia
5.1.1.1. Hemophilia market size and forecast, 2021-2031 (USD Million)
5.1.2. Primary Immunodeficiency Disorder (PID)
5.1.2.1. Primary immunodeficiency disorder (PID) market size and forecast, 2021-2031 (USD Million)
5.1.3. Idiopathic Thrombocytopenic Purpura
5.1.3.1. Idiopathic Thrombocytopenic Purpura market size and forecast, 2021-2031 (USD Million)
5.1.4. Secondary Immunodeficiency
5.1.4.1. Secondary Immunodeficiency market size and forecast, 2021-2031 (USD Million)
5.1.5. Hereditary Angioedema
5.1.5.1. Hereditary Angioedema market size and forecast, 2021-2031 (USD Million)
5.1.6. Other Indications
5.1.6.1. Other Indications market size and forecast, 2021-2031 (USD Million)
6. Global Plasma Protein Therapeutics Market Analysis and Forecast, 2021-2031 By Patient Demographics (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Geriatric
6.1.1.1. Geriatric market size and forecast, 2021-2031 (USD Million)
6.1.2. Adult
6.1.2.1. Adult market size and forecast, 2021-2031 (USD Million)
6.1.3. Pediatric
6.1.3.1. Pediatric market size and forecast, 2021-2031 (USD Million)
7. Global Plasma Protein Therapeutics Market Analysis and Forecast, 2021-2031 By End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Hospitals
7.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
7.1.2. Homecare
7.1.2.1. Homecare market size and forecast, 2021-2031 (USD Million)
7.1.3. Specialty Clinics
7.1.3.1. Specialty Clinics market size and forecast, 2021-2031 (USD Million)
7.1.4. Others
7.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
8. Global Plasma Protein Therapeutics Market Analysis and Forecast, 2021-2031 By Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. Hospitals Pharmacy
8.1.1.1. Hospitals Pharmacy market size and forecast, 2021-2031 (USD Million)
8.1.2. Retail Pharmacy
8.1.2.1. Retail Pharmacy market size and forecast, 2021-2031 (USD Million)
8.1.3. Online Pharmacies
8.1.3.1. Online Pharmacies market size and forecast, 2021-2031 (USD Million)
9. North America Plasma Protein Therapeutics Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. North America Plasma Protein Therapeutics Market Size and Forecast By Product
9.2.1.1. XX Driving/Opportunity Factor
9.2.1.2. XX Driving/Opportunity Factor
9.3. North America Plasma Protein Therapeutics Market Size and Forecast By Application
9.3.1.1. XX Driving/Opportunity Factor
9.3.1.2. XX Driving/Opportunity Factor
9.4. North America Plasma Protein Therapeutics Market Size and Forecast By Patient Demographics
9.4.1.1. XX Driving/Opportunity Factor
9.4.1.2. XX Driving/Opportunity Factor
9.5. North America Plasma Protein Therapeutics Market Size and Forecast By End-User
9.5.1.1. XX Driving/Opportunity Factor
9.5.1.2. XX Driving/Opportunity Factor
9.6. North America Plasma Protein Therapeutics Market Size and Forecast By Distribution Channel
9.6.1.1. XX Driving/Opportunity Factor
9.6.1.2. XX Driving/Opportunity Factor
9.7. U.S. Plasma Protein Therapeutics Market
9.7.1.1. XX Driving/Opportunity Factor
9.7.1.2. XX Driving/Opportunity Factor
9.8. Canada Plasma Protein Therapeutics Market
9.8.1.1. XX Driving/Opportunity Factor
9.8.1.2. XX Driving/Opportunity Factor
10. Europe Plasma Protein Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Europe Plasma Protein Therapeutics Market Size and Forecast By Product
10.2.1.1. XX Driving/Opportunity Factor
10.2.1.2. XX Driving/Opportunity Factor
10.3. Europe Plasma Protein Therapeutics Market Size and Forecast By Application
10.3.1.1. XX Driving/Opportunity Factor
10.3.1.2. XX Driving/Opportunity Factor
10.4. Europe Plasma Protein Therapeutics Market Size and Forecast By Patient Demographics
10.4.1.1. XX Driving/Opportunity Factor
10.4.1.2. XX Driving/Opportunity Factor
10.5. Europe Plasma Protein Therapeutics Market Size and Forecast By End-User
10.5.1.1. XX Driving/Opportunity Factor
10.5.1.2. XX Driving/Opportunity Factor
10.6. Europe Plasma Protein Therapeutics Market Size and Forecast By Distribution Channel
10.6.1.1. XX Driving/Opportunity Factor
10.6.1.2. XX Driving/Opportunity Factor
10.7. UK Plasma Protein Therapeutics Market
10.7.1.1. XX Driving/Opportunity Factor
10.7.1.2. XX Driving/Opportunity Factor
10.8. Germany Plasma Protein Therapeutics Market
10.8.1.1. XX Driving/Opportunity Factor
10.8.1.2. XX Driving/Opportunity Factor
10.9. France Plasma Protein Therapeutics Market
10.9.1.1. XX Driving/Opportunity Factor
10.9.1.2. XX Driving/Opportunity Factor
10.10. Rest of Europe Plasma Protein Therapeutics Market
10.10.1.1. XX Driving/Opportunity Factor
10.10.1.2. XX Driving/Opportunity Factor
11. Asia Pacific Plasma Protein Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. Asia-Pacific Plasma Protein Therapeutics Market Size and Forecast By Product
11.2.1.1. XX Driving/Opportunity Factor
11.2.1.2. XX Driving/Opportunity Factor
11.3. Asia-Pacific Plasma Protein Therapeutics Market Size and Forecast By Application
11.3.1.1. XX Driving/Opportunity Factor
11.3.1.2. XX Driving/Opportunity Factor
11.4. Asia-Pacific Plasma Protein Therapeutics Market Size and Forecast By Patient Demographics
11.4.1.1. XX Driving/Opportunity Factor
11.4.1.2. XX Driving/Opportunity Factor
11.5. Asia-Pacific Plasma Protein Therapeutics Market Size and Forecast By End-User
11.5.1.1. XX Driving/Opportunity Factor
11.5.1.2. XX Driving/Opportunity Factor
11.6. Asia-Pacific Plasma Protein Therapeutics Market Size and Forecast By Distribution Channel
11.6.1.1. XX Driving/Opportunity Factor
11.6.1.2. XX Driving/Opportunity Factor
11.7. China Plasma Protein Therapeutics Market
11.7.1.1. XX Driving/Opportunity Factor
11.7.1.2. XX Driving/Opportunity Factor
11.8. India Plasma Protein Therapeutics Market
11.8.1.1. XX Driving/Opportunity Factor
11.8.1.2. XX Driving/Opportunity Factor
11.9. Japan Plasma Protein Therapeutics Market
11.9.1.1. XX Driving/Opportunity Factor
11.9.1.2. XX Driving/Opportunity Factor
11.10. Rest of Asia Pacific Plasma Protein Therapeutics Market
11.10.1.1. XX Driving/Opportunity Factor
11.10.1.2. XX Driving/Opportunity Factor
12. Latin America Plasma Protein Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. Latin America Plasma Protein Therapeutics Market Size and Forecast By Product
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. Latin America Plasma Protein Therapeutics Market Size and Forecast By Application
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. Latin America Plasma Protein Therapeutics Market Size and Forecast By Patient Demographics
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. Latin America Plasma Protein Therapeutics Market Size and Forecast By End-User
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. Latin America Plasma Protein Therapeutics Market Size and Forecast By Distribution Channel
12.7. Brazil Plasma Protein Therapeutics Market
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. Mexico Plasma Protein Therapeutics Market
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. Rest of Latin America Plasma Protein Therapeutics Market
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
13. MEA Plasma Protein Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. MEA Plasma Protein Therapeutics Market Size and Forecast By Product
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. MEA Plasma Protein Therapeutics Market Size and Forecast By Application
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. MEA Plasma Protein Therapeutics Market Size and Forecast By Patient Demographics
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. MEA Plasma Protein Therapeutics Market Size and Forecast By End-User
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. MEA Plasma Protein Therapeutics Market Size and Forecast By Distribution Channel
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. GCC Plasma Protein Therapeutics Market
13.7.1.1. XX Driving/Opportunity Factor
13.7.1.2. XX Driving/Opportunity Factor
13.8. South Africa Plasma Protein Therapeutics Market
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. Rest of MEA Plasma Protein Therapeutics Market
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
14. Companies in the Plasma Protein Therapeutics Market
14.1. Baxter International
14.1.1. Company Snapshot
14.1.2. Company Overview
14.1.3. Financial Performance (2015-2019)
14.1.3.1. Net Revenue
14.1.3.2. Gross Profit
14.1.3.3. Geographical Revenue, 2019
14.1.4. Product Offerings
14.1.5. Recent Initiatives (2017-2019)
14.2. Biotests
14.2.1. Company Snapshot
14.2.2. Company Overview
14.2.3. Financial Performance (2015-2019)
14.2.3.1. Net Revenue
14.2.3.2. Gross Profit
14.2.3.3. Geographical Revenue, 2019
14.2.4. Product Offerings
14.2.5. Recent Initiatives (2017-2019)
14.3. CSL Behring
14.3.1. Company Snapshot
14.3.2. Company Overview
14.3.3. Financial Performance (2015-2019)
14.3.3.1. Net Revenue
14.3.3.2. Gross Profit
14.3.3.3. Geographical Revenue, 2019
14.3.4. Product Offerings
14.3.5. Recent Initiatives (2017-2019)
14.4. GRIFOLS, S.A
14.4.1. Company Snapshot
14.4.2. Company Overview
14.4.3. Financial Performance (2015-2019)
14.4.3.1. Net Revenue
14.4.3.2. Gross Profit
14.4.3.3. Geographical Revenue, 2019
14.4.4. Product Offerings
14.4.5. Recent Initiatives (2017-2019)
14.5. KEDRION
14.5.1. Company Snapshot
14.5.2. Company Overview
14.5.3. Financial Performance (2015-2019)
14.5.3.1. Net Revenue
14.5.3.2. Gross Profit
14.5.3.3. Geographical Revenue, 2019
14.5.4. Product Offerings
14.5.5. Recent Initiatives (2017-2019)
14.6. Octapharma USA, Inc.
14.6.1. Company Snapshot
14.6.2. Company Overview
14.6.3. Financial Performance (2015-2019)
14.6.3.1. Net Revenue
14.6.3.2. Gross Profit
14.6.3.3. Geographical Revenue, 2019
14.6.4. Product Offerings
14.6.5. Recent Initiatives (2017-2019)
14.7. Shire Plc.
14.7.1. Company Snapshot
14.7.2. Company Overview
14.7.3. Financial Performance (2015-2019)
14.7.3.1. Net Revenue
14.7.3.2. Gross Profit
14.7.3.3. Geographical Revenue, 2019
14.7.4. Product Offerings
14.7.5. Recent Initiatives (2017-2019)
14.8. China Biologics.
14.8.1. Company Snapshot
14.8.2. Company Overview
14.8.3. Financial Performance (2015-2019)
14.8.3.1. Net Revenue
14.8.3.2. Gross Profit
14.8.3.3. Geographical Revenue, 2019
14.8.4. Product Offerings
14.8.5. Recent Initiatives (2017-2019)
14.9. Emergent BioSolutions
14.9.1. Company Snapshot
14.9.2. Company Overview
14.9.3. Financial Performance (2015-2019)
14.9.3.1. Net Revenue
14.9.3.2. Gross Profit
14.9.3.3. Geographical Revenue, 2019
14.9.4. Product Offerings
14.9.5. Recent Initiatives (2017-2019)
14.10. Takeda Pharmaceutical Company Ltd
14.10.1. Company Snapshot
14.10.2. Company Overview
14.10.3. Financial Performance (2015-2019)
14.10.3.1. Net Revenue
14.10.3.2. Gross Profit
14.10.3.3. Geographical Revenue, 2019
14.10.4. Product Offerings
14.10.5. Recent Initiatives (2017-2019)
14.11. Other Notable Players
15. Conclusion
16. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Plasma Protein Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Plasma Protein Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Plasma Protein Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Plasma Protein Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Plasma Protein Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Plasma Protein Therapeutics Market Drivers & Restraints 2021
Table 7. Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Immunoglobulin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Immunoglobulin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Immunoglobulin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Immunoglobulin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Immunoglobulin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Albumin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Albumin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Albumin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Albumin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Albumin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Coagulation Factor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Coagulation Factor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Coagulation Factor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Coagulation Factor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Coagulation Factor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. C1-esterase Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. C1-esterase Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. C1-esterase Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. C1-esterase Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. C1-esterase Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Hemophilia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Hemophilia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Hemophilia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Hemophilia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Hemophilia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Primary Immunodeficiency Disorder (PID) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Primary Immunodeficiency Disorder (PID) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Primary Immunodeficiency Disorder (PID) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Primary Immunodeficiency Disorder (PID) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Primary Immunodeficiency Disorder (PID) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Secondary Immunodeficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Secondary Immunodeficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Secondary Immunodeficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Secondary Immunodeficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Secondary Immunodeficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Hereditary Angioedema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Hereditary Angioedema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Hereditary Angioedema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Hereditary Angioedema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Hereditary Angioedema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Other Indications Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Other Indications Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Other Indications Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Other Indications Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Other Indications Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 118. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 123. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 128. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 132. North America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 133. North America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 134. North America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 135. North America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 136. North America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 137. North America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 138. North America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 139. North America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 140. North America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 141. North America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 142. North America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 143. North America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 144. North America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 145. North America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 146. North America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 147. North America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 148. North America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 149. North America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150. North America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 151. North America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 152. North America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153. North America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. North America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 155. North America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 156. North America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157. North America Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. North America Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. North America Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. North America Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161. North America Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. US Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. US Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. US Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. US Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. US Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167. Canada Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168. Canada Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Canada Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Canada Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Canada Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Europe Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 173. Europe Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. Europe Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. Europe Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. Europe Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177. Europe Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. Europe Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. Europe Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. Europe Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. Europe Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. Europe Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183. Europe Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. Europe Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185. Europe Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. Europe Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. Europe Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. Europe Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. Europe Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. Europe Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191. Europe Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. Europe Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. Europe Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. Europe Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. Europe Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. Europe Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. Europe Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 198. Europe Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 199. Europe Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 200. Europe Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 201. UK Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 202. UK Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 203. UK Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 204. UK Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 205. UK Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 206. Germany Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 207. Germany Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 208. Germany Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 209. Germany Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 210. Germany Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 211. France Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 212. France Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 213. France Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 214. France Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 215. France Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 216. Rest of Europe Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 217. Rest of Europe Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 218. Rest of Europe Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 219. Rest of Europe Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 220. Rest of Europe Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 221. Asia Pacific Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 222. Asia Pacific Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 223. Asia Pacific Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 224. Asia Pacific Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 225. Asia Pacific Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 226. Asia Pacific Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 227. Asia Pacific Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 228. Asia Pacific Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 229. Asia Pacific Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 230. Asia Pacific Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 231. Asia Pacific Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 232. Asia Pacific Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 233. Asia Pacific Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 234. Asia Pacific Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 235. Asia Pacific Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 236. Asia Pacific Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 237. Asia Pacific Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 238. Asia Pacific Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 239. Asia Pacific Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 240. Asia Pacific Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 241. Asia Pacific Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 242. Asia Pacific Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 243. Asia Pacific Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 244. Asia Pacific Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 245. Asia Pacific Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 246. Asia Pacific Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 247. Asia Pacific Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 248. Asia Pacific Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 249. Asia Pacific Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 250. Asia Pacific Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 251. China Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 252. China Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 253. China Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 254. China Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 255. China Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 256. India Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 257. India Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 258. India Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 259. India Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 260. India Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 261. Japan Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 262. Japan Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 263. Japan Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 264. Japan Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 265. Japan Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 266. RoAPAC Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 267. RoAPAC Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 268. RoAPAC Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 269. RoAPAC Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 270. RoAPAC Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 271. Middle East Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 272. Middle East Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 273. Middle East Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 274. Middle East Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 275. Middle East Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 276. Middle East Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 277. Middle East Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 278. Middle East Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 279. Middle East Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 280. Middle East Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 281. Middle East Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 282. Middle East Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 283. Middle East Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 284. Middle East Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 285. Middle East Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 286. Middle East Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 287. Middle East Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 288. Middle East Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 289. Middle East Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 290. Middle East Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 291. Middle East Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 292. Middle East Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 293. Middle East Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 294. Middle East Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 295. Middle East Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 296. Latin America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 297. Latin America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 298. Latin America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 299. Latin America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 300. Latin America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 301. Latin America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 302. Latin America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 303. Latin America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 304. Latin America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 305. Latin America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 306. Latin America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 307. Latin America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 308. Latin America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 309. Latin America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 310. Latin America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 311. Latin America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 312. Latin America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 313. Latin America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 314. Latin America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 315. Latin America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 316. Latin America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 317. Latin America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 318. Latin America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 319. Latin America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 320. Latin America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 321. Africa Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 322. Africa Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 323. Africa Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 324. Africa Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 325. Africa Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 326. Africa Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 327. Africa Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 328. Africa Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 329. Africa Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 330. Africa Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 331. Africa Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 332. Africa Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 333. Africa Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 334. Africa Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 335. Africa Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 336. Africa Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 337. Africa Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 338. Africa Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 339. Africa Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 340. Africa Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 341. Africa Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 342. Africa Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 343. Africa Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 344. Africa Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 345. Africa Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 346. Leading 10 Plasma Protein Therapeutics Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 347. Baxter InternationalProfile 2019 (CEO, HQ, Founded, Website)
Table 348. Baxter International Plasma Protein Therapeutics Product Offering (Segment, Product Offerings)
Table 349. Biotests Profile 2019 (CEO, HQ, Founded, Website)
Table 350. Biotests Plasma Protein Therapeutics Product Offering (Segment, Product Offerings)
Table 351. CSL Behring Profile 2019 (CEO, HQ, Founded, Website)
Table 352. CSL Behring.Plasma Protein Therapeutics Product Offering (Segment, Product Offerings)
Table 353. GRIFOLS, S.A Profile 2019 (CEO, HQ, Founded, Website)
Table 354. GRIFOLS, S.A Plasma Protein Therapeutics Product Offering (Segment, Product Offerings)
Table 355. KEDRION Profile 2019 (CEO, HQ, Founded, Website)
Table 356. KEDRION Plasma Protein Therapeutics Product Offering (Segment, Product Offerings)
Table 357. Octapharma USA, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 358. Octapharma USA, Inc. Plasma Protein Therapeutics Product Offering (Segment, Product Offerings)
Table 359. Shire Plc. Profile 2019 (CEO, HQ, Founded, Website)
Table 360. Shire Plc. Plasma Protein Therapeutics Product Offering (Segment, Product Offerings)
Table 361. China Biologics. Profile 2019 (CEO, HQ, Founded, Website)
Table 362. China Biologics. Plasma Protein Therapeutics Product Offering (Segment, Product Offerings)
Table 363. Emergent BioSolutions Profile 2019 (CEO, HQ, Founded, Website)
Table 364. Emergent BioSolutions Plasma Protein Therapeutics Product Offering (Segment, Product Offerings)
Table 365. Takeda Pharmaceutical Company Ltd Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 366. Takeda Pharmaceutical Company Ltd Plasma Protein Therapeutics Product Offering (Segment, Product Offerings)
Table 367. Other Companies Involved in the Plasma Protein Therapeutics Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Plasma Protein Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Plasma Protein Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Plasma Protein Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Plasma Protein Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Plasma Protein Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Plasma Protein Therapeutics Market Drivers & Restraints 2021
Figure 7. Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. Immunoglobulin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. Immunoglobulin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. Immunoglobulin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. Immunoglobulin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. Immunoglobulin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Albumin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Albumin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Albumin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Albumin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Albumin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Coagulation Factor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Coagulation Factor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Coagulation Factor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Coagulation Factor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Coagulation Factor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. C1-esterase Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. C1-esterase Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. C1-esterase Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. C1-esterase Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. C1-esterase Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 33. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Hemophilia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Hemophilia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Hemophilia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Hemophilia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Hemophilia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Primary Immunodeficiency Disorder (PID) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Primary Immunodeficiency Disorder (PID) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Primary Immunodeficiency Disorder (PID) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Primary Immunodeficiency Disorder (PID) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Primary Immunodeficiency Disorder (PID) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Secondary Immunodeficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Secondary Immunodeficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Secondary Immunodeficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Secondary Immunodeficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Secondary Immunodeficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Hereditary Angioedema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Hereditary Angioedema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Hereditary Angioedema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Hereditary Angioedema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Hereditary Angioedema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Other Indications Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Other Indications Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Other Indications Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Other Indications Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Other Indications Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 118. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 123. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 128. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. North America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 133. North America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. North America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. North America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. North America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. North America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 138. North America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. North America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. North America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. North America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. North America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 143. North America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 144. North America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 145. North America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 146. North America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 147. North America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 148. North America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 149. North America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 150. North America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 151. North America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 152. North America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 153. North America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 154. North America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 155. North America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 156. North America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 157. North America Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 158. North America Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 159. North America Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 160. North America Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 161. North America Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 162. US Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 163. US Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 164. US Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 165. US Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 166. US Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 167. Canada Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 168. Canada Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 169. Canada Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 170. Canada Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 171. Canada Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 172. Europe Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 173. Europe Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 174. Europe Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 175. Europe Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 176. Europe Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 177. Europe Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 178. Europe Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 179. Europe Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 180. Europe Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 181. Europe Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 182. Europe Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 183. Europe Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 184. Europe Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 185. Europe Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 186. Europe Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 187. Europe Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 188. Europe Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 189. Europe Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 190. Europe Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 191. Europe Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 192. Europe Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 193. Europe Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 194. Europe Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 195. Europe Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 196. Europe Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 197. Europe Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 198. Europe Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 199. Europe Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 200. Europe Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 201. UK Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 202. UK Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 203. UK Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 204. UK Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 205. UK Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 206. Germany Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 207. Germany Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 208. Germany Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 209. Germany Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 210. Germany Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 211. France Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 212. France Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 213. France Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 214. France Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 215. France Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 216. Rest of Europe Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 217. Rest of Europe Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 218. Rest of Europe Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 219. Rest of Europe Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 220. Rest of Europe Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 221. Asia Pacific Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 222. Asia Pacific Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 223. Asia Pacific Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 224. Asia Pacific Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 225. Asia Pacific Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 226. Asia Pacific Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 227. Asia Pacific Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 228. Asia Pacific Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 229. Asia Pacific Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 230. Asia Pacific Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 231. Asia Pacific Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 232. Asia Pacific Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 233. Asia Pacific Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 234. Asia Pacific Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 235. Asia Pacific Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 236. Asia Pacific Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 237. Asia Pacific Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 238. Asia Pacific Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 239. Asia Pacific Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 240. Asia Pacific Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 241. Asia Pacific Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 242. Asia Pacific Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 243. Asia Pacific Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 244. Asia Pacific Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 245. Asia Pacific Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 246. Asia Pacific Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 247. Asia Pacific Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 248. Asia Pacific Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 249. Asia Pacific Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 250. Asia Pacific Plasma Protein Therapeutics Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 251. China Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 252. China Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 253. China Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 254. China Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 255. China Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 256. India Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 257. India Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 258. India Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 259. India Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 260. India Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 261. Japan Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 262. Japan Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 263. Japan Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 264. Japan Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 265. Japan Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 266. RoAPAC Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 267. RoAPAC Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 268. RoAPAC Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 269. RoAPAC Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 270. RoAPAC Plasma Protein Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 271. Middle East Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 272. Middle East Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 273. Middle East Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 274. Middle East Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 275. Middle East Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 276. Middle East Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 277. Middle East Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 278. Middle East Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 279. Middle East Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 280. Middle East Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 281. Middle East Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 282. Middle East Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 283. Middle East Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 284. Middle East Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 285. Middle East Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 286. Middle East Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 287. Middle East Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 288. Middle East Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 289. Middle East Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 290. Middle East Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 291. Middle East Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 292. Middle East Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 293. Middle East Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 294. Middle East Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 295. Middle East Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 296. Latin America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 297. Latin America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 298. Latin America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 299. Latin America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 300. Latin America Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 301. Latin America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 302. Latin America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 303. Latin America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 304. Latin America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 305. Latin America Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 306. Latin America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 307. Latin America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 308. Latin America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 309. Latin America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 310. Latin America Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 311. Latin America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 312. Latin America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 313. Latin America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 314. Latin America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 315. Latin America Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 316. Latin America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 317. Latin America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 318. Latin America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 319. Latin America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 320. Latin America Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 321. Africa Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 322. Africa Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 323. Africa Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 324. Africa Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 325. Africa Plasma Protein Therapeutics Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 326. Africa Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 327. Africa Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 328. Africa Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 329. Africa Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 330. Africa Plasma Protein Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 331. Africa Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 332. Africa Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 333. Africa Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 334. Africa Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 335. Africa Plasma Protein Therapeutics Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 336. Africa Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 337. Africa Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 338. Africa Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 339. Africa Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 340. Africa Plasma Protein Therapeutics Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 341. Africa Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 342. Africa Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 343. Africa Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 344. Africa Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 345. Africa Plasma Protein Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 346. Porter’s Five Force Analysis
Companies Mentioned
1. AbbVie
2. Achaogen
3. Actavis
4. Actelion
5. Affinium Pharmaceutical
6. AiCuris GmbH & Co. KG
7. Alcon
8. Alkem Laboratories
9. Allergan
10. Allied Pharma
11. Apotex
12. APP Pharmaceuticals
13. Aptalis Pharma
14. Aquapharm Biodiscovery
15. Cempra Pharmaceuticals
16. Cipla
17. Claris Lifesciences
18. Cornerstone Biopharma
19. Cornerstone Therapeutics
20. Corona Remedies
21. Eli Lilly
22. Gate Pharma
23. Gilead Sciences
24. GlaxoSmithKline (GSK)
25. Glenmark
26. GlycoVaxyn
27. Hetero
28. Hikma Farmaceutica
29. Hi-Tech Pharma
30. Hospira
31. Macleod Pharmaceuticals
32. Microlabs
33. Nalneva
34. Novartis
35. Novexel
36. Paratek Pharmaceuticals
37. Pfizer
38. Ranbaxy
39. Roche
40. Sagent Pharmaceuticals
41. Sandoz
42. Sanofi
43. Sequella
44. Shanghai MengKe Pharmaceuticals
45. Shionogi
46. SHIONOGI Co., Ltd.
47. Shire
48. Sidmak Labs
49. Solitaire Pharmacia
50. Specialised Therapeutics Australia
Companies Profiled in the Report
1. Baxter International
2. Biotests
3. CSL Behring
4. GRIFOLS, S.A
5. Kedrion
6. Octapharma USA, Inc.
7. Shire Plc.
8. China Biologics.
9. Emergent BioSolutions
10. Takeda Pharmaceutical Company Ltd
List of Companies Mentioned in the Report:
1. AbbVie
2. Achaogen
3. Actavis
4. Actelion
5. Affinium Pharmaceutical
6. AiCuris GmbH & Co. KG
7. Alcon
8. Alkem Laboratories
9. Allergan
10. Allied Pharma
11. Apotex
12. APP Pharmaceuticals
13. Aptalis Pharma
14. Aquapharm Biodiscovery
15. Cempra Pharmaceuticals
16. Cipla
17. Claris Lifesciences
18. Cornerstone Biopharma
19. Cornerstone Therapeutics
20. Corona Remedies
21. Eli Lilly
22. Gate Pharma
23. Gilead Sciences
24. GlaxoSmithKline (GSK)
25. Glenmark
26. GlycoVaxyn
27. Hetero
28. Hikma Farmaceutica
29. Hi-Tech Pharma
30. Hospira
31. Macleod Pharmaceuticals
32. Microlabs
33. Nalneva
34. Novartis
35. Novexel
36. Paratek Pharmaceuticals
37. Pfizer
38. Ranbaxy
39. Roche
40. Sagent Pharmaceuticals
List of Organizations Mentioned in the Report:
1. Centre for Pharmaceutical Administration Health Sciences Authority
2. Central Drug Standard Control Organization (CDSCO)
3. Organisation for Economic Co-operation and Development (OECD)
4. European Medicines Agency (EMA)
5. Food and Drug Administration (FDA)
6. National Institutes of Health (NIH)
7. United Nations (UN)
8. United Nations Office on Drugs and Crime (UNODC)
9. United Nations Statistics Division (UNSD)
10. Statistical Office of the European Union (EUROSTAT)
11. World Health Organization (WHO)
12. The National Medical Products Administration (NMPA)
13. Indian Council of Medical Research (ICMR)
14. The Federal Institute for Drugs and Medical Devices (BfArM)
15. Pharmaceuticals and Medical Devices Agency (PMDA)
1. Baxter International
2. Biotests
3. CSL Behring
4. GRIFOLS, S.A
5. Kedrion
6. Octapharma USA, Inc.
7. Shire Plc.
8. China Biologics.
9. Emergent BioSolutions
10. Takeda Pharmaceutical Company Ltd
List of Companies Mentioned in the Report:
1. AbbVie
2. Achaogen
3. Actavis
4. Actelion
5. Affinium Pharmaceutical
6. AiCuris GmbH & Co. KG
7. Alcon
8. Alkem Laboratories
9. Allergan
10. Allied Pharma
11. Apotex
12. APP Pharmaceuticals
13. Aptalis Pharma
14. Aquapharm Biodiscovery
15. Cempra Pharmaceuticals
16. Cipla
17. Claris Lifesciences
18. Cornerstone Biopharma
19. Cornerstone Therapeutics
20. Corona Remedies
21. Eli Lilly
22. Gate Pharma
23. Gilead Sciences
24. GlaxoSmithKline (GSK)
25. Glenmark
26. GlycoVaxyn
27. Hetero
28. Hikma Farmaceutica
29. Hi-Tech Pharma
30. Hospira
31. Macleod Pharmaceuticals
32. Microlabs
33. Nalneva
34. Novartis
35. Novexel
36. Paratek Pharmaceuticals
37. Pfizer
38. Ranbaxy
39. Roche
40. Sagent Pharmaceuticals
List of Organizations Mentioned in the Report:
1. Centre for Pharmaceutical Administration Health Sciences Authority
2. Central Drug Standard Control Organization (CDSCO)
3. Organisation for Economic Co-operation and Development (OECD)
4. European Medicines Agency (EMA)
5. Food and Drug Administration (FDA)
6. National Institutes of Health (NIH)
7. United Nations (UN)
8. United Nations Office on Drugs and Crime (UNODC)
9. United Nations Statistics Division (UNSD)
10. Statistical Office of the European Union (EUROSTAT)
11. World Health Organization (WHO)
12. The National Medical Products Administration (NMPA)
13. Indian Council of Medical Research (ICMR)
14. The Federal Institute for Drugs and Medical Devices (BfArM)
15. Pharmaceuticals and Medical Devices Agency (PMDA)
Download sample pages
Complete the form below to download your free sample pages for Plasma Protein Therapeutics Market Report 2021-2031Download sample pages
Complete the form below to download your free sample pages for Plasma Protein Therapeutics Market Report 2021-2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Single-Cell Analysis Market Report 2022-2032
The global single cell analysis market was valued at US$3,255.0 million in 2022 and is projected to grow at a CAGR of 15.1% during the forecast period 2022-2032.
26 May 2022
Visiongain Publishes Ophthalmic Devices Market Report 2022-2032
The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.
19 April 2022
Visiongain Publishes Vaccine Contract Manufacturing Market Report 2022-2032
The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet
13 April 2022
Visiongain Publishes Pharmaceutical Contract Manufacturing Market Report 2022-2032
The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.
13 April 2022
